Introduction
============

AMD is a progressive degenerative disease of the retina, whose incidence increases with age and it can cause severe visual impairment and even blindness in some serious cases.[@b1-cia-13-051] The condition mostly occurs in middle-aged patients, at an approximate age of 50 years[@b1-cia-13-051],[@b2-cia-13-051] and is one of the three major causes of blindness in the world.[@b2-cia-13-051],[@b3-cia-13-051] Predictive estimates indicate that by 2020 AMD prevalence will affect more than 3 million people in the USA alone. Along with the changing social structure of an aging population, this unfavorable trend will be observed not only in the USA but also globally. AMD is considered to become an increasingly important, globally prevalent social issue in the future.

Two main types of AMD exist based on its clinical manifestations: atrophy type (dry or non-exudative) and exudation type (wet).[@b4-cia-13-051] The early stages of AMD are usually asymptomatic or characterized by minor symptoms. In general, drusen and pigmentary changes are present within the macula.[@b5-cia-13-051],[@b6-cia-13-051] Due to the phagocytic activities of the retinal pigment epithelial cells, the availability of discs containing visual pigment molecules is reduced, which causes malignant development of AMD.[@b7-cia-13-051],[@b8-cia-13-051] As a result, the remaining undissociated membrane discs are retained in the basal cell mycelia and excreted to extracellular space. Eventually, the residual bodies of the membrane discs are deposited on the Bruch's membrane, forming a drusen, which is a small yellowish macular lesion or speck. These fundus pathological changes are obvious due to the specific properties of the structure and function of the macula. A variety of pathological changes can lead to macular degeneration, and thus drusens are also found in elderly with normal vision. During disease progression, the Bruch's membrane is disrupted and subsequently locally dissolved.[@b9-cia-13-051]--[@b11-cia-13-051] Through the rupture of the Bruch's membrane, the choriocapillaris penetrates under the retinal pigmented epithelium and retinal neurosensory layer, and CNV is formed, which is one of the hallmarks of AMD.[@b2-cia-13-051] Without treatment, CNV can cause destruction of the macular structures, including the retinal pigment epithelium cells and the photoreceptors, resulting in the development of a disciform scar and associated severe central visual loss.[@b9-cia-13-051],[@b12-cia-13-051] The resulting structural abnormalities in the new blood vessel wall facilitate the occurrence of vascular leakage and bleeding, which subsequently trigger a series of secondary pathological changes.

Although the etiological and pathophysiological mechanisms of AMD are not yet elucidated, an extensive abnormal ocular neovascularization has been recognized as the main reason leading to blindness of AMD patients. VEGF promotes abnormal vascular proliferation in AMD patients.[@b13-cia-13-051]--[@b16-cia-13-051] VEGF-A belongs to the VEGF family, which includes six isoforms: VEGF-A, PlGF1, PIGF2, VEGF-B, VEGF-C, and VEGF-D. Each of these isoforms can bind to a specific combination of three vascular endothelial growth factor receptors of VEGFR-1, -2, and -3.[@b17-cia-13-051],[@b18-cia-13-051] Currently, anti-VEGF drugs have been widely used for AMD treatment, achieving promising clinical results. At present, three anti-VEGF agents have been approved by the US FDA for the treatment of AMD: pegaptanib,[@b19-cia-13-051] ranibizumab,[@b20-cia-13-051] and the newly registered aflibercept.[@b21-cia-13-051]

Recently, conbercept was approved by the China Food and Drug Administration for the treatment of neovascular AMD in China.[@b2-cia-13-051],[@b22-cia-13-051] This common name of China's first new "biological" classes of drugs with entirely independent intellectual property rights that has been internationally recognized. Conbercept is a genetically engineered homodimeric protein that inhibits the activity of VEGF-family proteins, and is used for the treatment of wet AMD.[@b23-cia-13-051],[@b24-cia-13-051] Similar to VEGF Trap-Eye, conbercept (also named KH902;[@b23-cia-13-051],[@b24-cia-13-051] Chengdu Kanghong Biotech Co., Ltd., Sichuan, China) is a recombinant, soluble, VEGF-receptor protein that was designed as a receptor decoy composed of the second Ig domain of VEGFR-1, and the third and fourth Ig domains of VEGFR-2, and the constant region (Fc) of the human IgG1. Previous studies have demonstrated that domain 4 of VEGF receptor 2 is essential for receptor dimerization and enhances the rate of VEGF association to the receptor.[@b25-cia-13-051] Preclinical examinations have shown that conbercept binds to and neutralizes VEGF-A and all its isoforms, which results in a binding affinity that is higher than that of ranibizumab.[@b24-cia-13-051],[@b26-cia-13-051] Moreover, conbercept shows a higher PlGF-binding activity compared with ranibizumab.

Conbercept has been used in clinic practice throughout China. However, at present, most of the data concerning the administration of conbercept in China are provided by clinical trials with non-standardized design, and, unlike other anti-VEGF drugs, consensus has still not been reached on its clinical safety and efficacy, dose, and optimal methods for clinical application.

Therefore, there is an urgent need to apply these findings in clinical practice to provide better treatment for AMD on the global scale. Thus, we performed this meta-analysis of RCTs to investigate the effects of the application of conbercept in AMD treatment.

Methods
=======

Literature search
-----------------

An electronic literature search was conducted on PubMed, Web of Science, EMBASE, Cochrane library databases, China National Knowledge Internet, and Wanfang Data. The search keywords and terms used were combined as follows: "Conbercept, KH902, FP3" and/or "Ranibizumab, Triamcinolone, traditional transpupillary thermotherapy", and "Age-related macular degeneration, AMD, macular degeneration, Macular disease". The search results were limited to randomized clinical trials. We searched by keywords and read the title, abstract, and full text to select the English and Chinese articles. The final search was carried out on October 2016. As it is a meta-analysis, ethical approval is not required.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria were as follows: 1) Study design: randomized clinical controlled trials involving AMD patients; 2) patients: enrollment of middle-aged and elderly patients with AMD in the studies; 3) therapeutic methods: setup of a control treatment in all examinations; and 4) data: ability to quantify all the data of results of all articles.

The following exclusion criteria were utilized: 1) no control group in the clinical trials (including self-, pre-, and post-control); 2) patients suffering from another macular disease; 3) experimental data not quantified in the publication; and 4) case reports, editorials, meeting abstracts, animal, and cell experimental studies.

Outcome measures
----------------

The following indicators and definitions were used to evaluate the outcomes of the trials: 1) eyesight: Early Treatment Diabetic Retinopathy Study (ETDRS) charts were use to obtain the mean changes of BCVA. Further, the data were recorded as dichotomous and continuous variables. For the dichotomous variable data, obviously effective and effective transformation were considered to represent a satisfactory clinical effect (total effective rate = obviously effective + effective). Obviously effective: visual acuity improved by two or more lines after treatment; effective: visual acuity improved by one line or visual acuity improved from light perception to 0.1; ineffective: vision without any improvement after treatment. 2) CRT: determined by using ocular coherence tomography. The scanning mode was selected by horizontal and vertical direction linear scan through fovea and quantitative measurement; and 3) the concentration of VEGF (ng/L) was determined in the serum extract according to the inclusion criteria.

Data extraction
---------------

Two reviewers independently extracted data for each article included in the study. If inconsistencies were encountered, they were resolved by discussion and analysis. The basic information of the experimental and control groups of patients was extracted from each article ([Table 1](#t1-cia-13-051){ref-type="table"}). We performed post-treatment assessments of the data for BCVA and CRT to impute a change-from-baseline SD using a correlation coefficient.

Quality assessment
------------------

We used the "Cochrane Handbook for Systematic Reviews of Interventions" to assess the risk of bias to evaluate the quality of the trials included. Six parameters concerning the quality of the RCTs were observed in the trials: 1) sequence generation, 2) allocation concealment, 3) patient blinding, 4) personnel and outcome assessors, 5) management of incomplete outcome data, and 6) selective outcome reporting. There were three possible choices for each parameter. "Yes" represented a low risk of bias, "no" indicated a high risk of bias, and "unclear" denoted unclear or unknown risk of bias.

Statistical analysis
--------------------

Stata version 12.0 (Stata Corp, College Station, TX, USA) was used for the meta-analysis. Risk ratios were used in the comparisons of dichotomous variables data. Weighted mean differences and standard mean differences were employed in the comparisons of continuous variables data. All statistical analyses were conducted with 95% confidence intervals. We utilized *I*^2^ to evaluate the heterogeneity among studies. Heterogeneity was considered to be low when *I*^2^≤50% in dichotomous and continuous variables, and the data were analyzed by using the fixed-effects model. If *I*^2^\>50%, we accepted that the differences across studies were heterogeneous, and the random-effects model was employed for the data analysis. As baseline continuous variable data, we used those of the experimental group (E) and the control group (C) established before the treatment (baseline mean1~E,C~, SD1~E,C~), whereas the posttreatment ones were utilized as final data (final mean2~E,C~, SD2~E,C~). To eliminate the deviation caused by the difference of baseline SD, mean3~E,C~ and SD~3E,C~ were used to the following formula as change mean ± SD. The following formula was used to calculate the missing SD values for changes from baseline:[@b27-cia-13-051],[@b28-cia-13-051] $$\begin{array}{l}
{\text{Mean}3_{E,C} = \text{Mean}_{E,C} - \text{Mean}1_{E,C};} \\
{\text{SD}3_{E,C} = \sqrt[2]{\text{SD}1_{E,C}{}^{2} + \text{SD}2_{E,C}{}^{2} - (2*\text{Corr}*\text{SD}1_{E,C}*\text{SD}2_{E,C})}} \\
\end{array}$$where Corr is the coefficient of correlation between the experimental and control groups. If the value of Corr was not possible to calculate for all the data, the statistics point of view is usually the default of 0.4 or 0.5. In this study, we adopted a value of Corr =0.4, and by using the method described earlier, we obtained the change-from-baseline SD for the experimental and control groups.

Results
=======

Selection and characteristics of the studies
--------------------------------------------

Initially, a total of 556 potentially relevant articles were identified by the literature search. Then, 480 articles were excluded because they did not meet the inclusion criteria. After reading the title and the abstract of each of the remaining 76 articles, we excluded another 52 articles from our analysis. Further, we read the full text of the remaining 24 articles and excluded 11 articles that did not adhere strictly to our inclusion criteria. Finally, 13 articles remained, among which four investigated the effects of ranibizumab,[@b29-cia-13-051]--[@b32-cia-13-051] six triamcinolone,[@b33-cia-13-051]--[@b38-cia-13-051] and three TTT.[@b39-cia-13-051]--[@b41-cia-13-051] Fundus examination of the parameters data analysis was carried out to find the differences between the conbercept treatment group and each of others control group. The trial selection process is presented in [Figure 1](#f1-cia-13-051){ref-type="fig"}, and the summarized basic information and the details of the 13 articles are shown in [Table 1](#t1-cia-13-051){ref-type="table"}. All studies were RCTs conducted in clinical settings. No special emphasis was placed on drug manufacturers, although their recommended dosage was generally utilized in the trials.

Conbercept and ranibizumab
--------------------------

The 1-month treatment of AMD patients with conbercept did not lead to a significant improvement in their BCVA as compared with the respective values obtained after the therapy with ranibizumab for the same period of time ([Figure 2A](#f2-cia-13-051){ref-type="fig"}; *Z*=1.03, *P*=0.301; *I*^2^=95%, *P*=0.000).[@b29-cia-13-051],[@b30-cia-13-051] After a 3-month treatment period, we obtained the same result for the level of CRT improvement in AMD patients ([Figure 2B](#f2-cia-13-051){ref-type="fig"}; *Z*=0.02, *P*=0.988; *I*^2^=49.8%, *P*=0.136; [Table 2](#t2-cia-13-051){ref-type="table"}).[@b29-cia-13-051]--[@b31-cia-13-051]

In addition, two articles reported different levels of VEGF after 1 month of treatment.[@b29-cia-13-051],[@b32-cia-13-051] Conbercept reduced VEGF serum levels more significantly than ranibizumab ([Figure 2C](#f2-cia-13-051){ref-type="fig"}; *Z*=3.54, *P*=0.000; *I*^2^=0.0%, *P*=0.715).

Conbercept and triamcinolone
----------------------------

After 3 months of treatment, a significant improvement was observed for BCVA in patients treated with conbercept compared with those treated with triamcinolone (3-month continuous variables:[@b35-cia-13-051],[@b36-cia-13-051],[@b38-cia-13-051] *Z*=1.98, *P*=0.048; *I*^2^=79.2%, *P*=0.008; 3-month dichotomous variables:[@b34-cia-13-051],[@b35-cia-13-051] *Z*=2.76, *P*=0.006; *I*^2^=0%, *P*=0.748; [Figures 3](#f3-cia-13-051){ref-type="fig"} and [4](#f4-cia-13-051){ref-type="fig"}). However, there was no difference between the experimental group and the control group after 1 month of treatment (1-month continuous variables:[@b35-cia-13-051],[@b36-cia-13-051],[@b38-cia-13-051] *Z*=1.43, *P*=0.151; *I*^2^=91.7%, *P*=0.000; 1-month dichotomous variables:[@b35-cia-13-051],[@b37-cia-13-051] *Z*=0.89, *P*=0.71; *I*^2^=89.8%, *P*=0.002; [Figures 3](#f3-cia-13-051){ref-type="fig"} and [4](#f4-cia-13-051){ref-type="fig"}). The continuous and dichotomous variables obtained exhibited the same trend for BCVA improvement in the conbercept- and triamcinolone-treated groups after 1 and 3 months of treatment. The results concerning BCVA improvement obtained after 3-month treatment were better than those obtained after 1-month treatment (*Z*=2.57, *P*=0.010; *I*^2^=87.3%, *P*=0.00; [Figures 3](#f3-cia-13-051){ref-type="fig"} and [4](#f4-cia-13-051){ref-type="fig"}).[@b35-cia-13-051],[@b36-cia-13-051],[@b38-cia-13-051]

Based on the continuous variable data obtained, we found that CRT improved more significantly in the conbercept-treated group than in the triamcinolone-treated group after 1 month[@b35-cia-13-051],[@b36-cia-13-051],[@b38-cia-13-051] and 3 months[@b33-cia-13-051],[@b35-cia-13-051],[@b36-cia-13-051] of treatment ([Figure 5](#f5-cia-13-051){ref-type="fig"}).

Comparative effects of conbercept and TTT
-----------------------------------------

Analysis of dichotomous outcome data for three of the studies[@b39-cia-13-051]--[@b41-cia-13-051] showed that the improvement in patients' BCVA after 1, 3, and 6 months of conbercept treatment was significantly higher than those achieved after TTT treatment (1-month treatment: *Z*=2.37, *P*=0.018; *I*^2^=53.91%, *P*=0.114; 3-month treatment: *Z*=4.07, *P*=0.000; *I*^2^=11.1%, *P*=0.325; 6-month treatment *Z*=7.21, *P*=0.000; *I*^2^=0.0%, *P*=0.787; [Figure 6](#f6-cia-13-051){ref-type="fig"}).

The continuous variables of three studies indicated that after 6 months of treatment with conbercept, patients' CRTs were significantly improved compared to those achieved after the treatment with TTT (*Z*=2.83, *P*=0.005; *I*^2^=0.0%, *P*=0.880). There was no statistically significant difference between the experimental group and control group after 1 month and 3 months of treatment (1-month treatment: *Z*=0.52, *P*=0.605; *I*^2^=0.000, *P*=0.906; 3-month treatment: *Z*=0.80, *P*=0.426; *I*^2^=0.000, *P*=0.858; [Figure 7](#f7-cia-13-051){ref-type="fig"}).[@b39-cia-13-051],[@b40-cia-13-051]

To explore the potential sources of heterogeneity in the present meta-analysis, we conducted several subgroup analyses. Due to the difference in the treatment methods, the number of patients, medication time and drug times, dosage and surgical operations contributed to heterogeneity. To eliminate this heterogeneity, we used strict inclusion criteria and excluded the obviously low-quality articles. We also used the fixed-effects model to exclude the results of no or low heterogeneity, whereas in cases of high heterogeneity of results, we employed the random-effect model.

Publication bias
----------------

Since there were few articles in each of the three control groups, this would inevitably have led to a certain degree of publication bias. There might have also been unpublished literature. All of these causes can contribute to publication bias. The instructions in the *Cochrane Handbook for Systematic Reviews of Interventions* were followed to assess the risk of bias and to evaluate the quality of the trials included ([Figure 8](#f8-cia-13-051){ref-type="fig"}).[@b42-cia-13-051]

Discussion
==========

Conbercept, a genetically engineered homodimeric protein that functions by blocking VEGF-family proteins, is used for the treatment of AMD.[@b2-cia-13-051] It is China's first biological class of new drugs with fully independent intellectual property rights and an internationally recognized common name included in WHO's database. Currently, it is widely used in the clinical treatment of AMD. However, the data concerning its clinical application have not been systematically sorted out. Subsequently, by conducting the present meta-analysis, we aimed at selecting, collecting, and assessing the studies on the clinical applications of conbercept.

Only two inhibitors of VEGF (pegaptanib and ranibizumab) approved by the US FDA for the treatment of exudative AMD and under commercial development since 2008 were available before the development of conbercept.[@b25-cia-13-051] However, both of them have to be injected into patients every 4 to 6 weeks to maintain a therapeutic level of VEGF inhibition. In an attempt to eliminate these limitations, Zhang et al[@b43-cia-13-051] developed this improved VEGF inhibitor that exerts more potent effects and can be administered less frequently. Conbercept has a high affinity for all VEGF isoforms and PlGF. It is a recombinant fusion protein that is composed of human VEGF receptor 1 domain 2 and human VEGF receptor 2 domains 3 and 4, and the Fc portion of human IgG1.[@b23-cia-13-051],[@b24-cia-13-051],[@b43-cia-13-051] Conbercept was also named KH902 or FP3 before its application in clinical practice.[@b44-cia-13-051]--[@b46-cia-13-051] It is produced by Chinese hamster ovary cell lines.[@b43-cia-13-051] The researchers who developed conbercept aimed to demonstrate its efficacy in the treatment of lesions in a monkey model of a laser-induced lesion, CNV. The results showed that the CNV leakage was obviously smaller than it was before the injection; moreover, there was no leakage at the end of the observation (after the injection was administered). In the next (Phase I) study, the authors selected 28 patients who suffered from CNV resulting from exudative AMD[@b24-cia-13-051] and applied different doses (from 0.05 to 3 mg) of the drug. Follow-up examinations were performed on post-injection days 1, 3, 5, 7, 14, 28, and 42. The treatment with conbercept was found to exert adequate clinical effects on BCVA, CRT, and CNV in this Phase I study. Later, Li et al[@b23-cia-13-051] conducted a twelve-month randomized Phase II study on the efficacy and safety of conbercept in the therapy of neovascular AMD. Patients were randomly divided into two groups with an equal number, in which two different doses of the drug (0.5 and 2.0 mg) were administered for three consecutive months. After the 3-month treatment, BCVA was the same as or better than those observed after 12 months of treatment in both the conbercept dose groups of neovascular AMD patients. Importantly, repeated intravitreal injections of conbercept were well tolerated in AMD patients. At present, as the clinical, randomized, double-masked, and controlled-dose experiment has been successfully completed, conbercept is widely used for the treatment of AMD patients.

In the present study, we compared the effects obtained after the treatment of patients with AMD with conbercept with those obtained after the application of other therapeutic methods. Ranibizumab was the first VEGF inhibitor to be approved by the US FDA for exudative AMD treatment. Nevertheless, the results of some studies evidenced that the 1-day injection with ranibizumab had a minimal effect on the serum or plasma VEGF level, which reached initial therapeutic level soon afterward. Similarly, the obtained systemic VEGF level was sustained over 1 month in the serum or plasma of AMD patients treated with bevacizumab.[@b47-cia-13-051]--[@b50-cia-13-051] There were no significant differences in the improvement of BCVA and CRT between the group treated with conbercept and that treated with ranibizumab. However, the 1-month treatment with conbercept lowered the serum VEGF level more considerably than that with bevacizumab, and the difference was statistically significant.

Triamcinolone is a long-acting cortical hormone produced by the adrenal gland that is artificially synthesized and widely used in the treatment of AMD, macular edema, and uveitis.[@b51-cia-13-051] The findings of our study indicate that after 3 months of treatment with conbercept, appreciable BCVA improvement was achieved (*P*\<0.05). Compared with triamcinolone, conbercept can significantly reduce the thickness of CRT. Thus, we speculate that conbercept is likely to have a better long-term effect in the treatment of AMD patients than triamcinolone.

TTT is employed in the treatment of eye diseases. For example, semiconductor infrared laser irradiation with a wavelength of 810 nm is usually applied for therapy of macular lesions. And it achieved the treatment effect treatment of AMD patients by to increase the local retina temperature.[@b52-cia-13-051],[@b53-cia-13-051]

In our meta-analysis, we found that the application of conbercept improved BCVA in AMD patients. The positive effects of the 6-month treatment with conbercept on CRT thickness were more pronounced than those achieved by TTT. This finding suggests that the treatment of AMD patients with conbercept is superior to that with TTT. In particular, the effect was more obvious after the long-term treatment with the drug.

Recent research shows that the combination of PDT and anti-VEGF drugs is superior to using either alone. In an earlier study, triple therapy was investigated that was designed for the treatment of neovascular AMD consisting of PDT, an anti-VEGF drug (intravitreal bevacizumab), and intravitreal triamcinolone.[@b51-cia-13-051] It seems that the application of the triple therapy showed a better effect than the single therapy administered for a short period of time. This result provides a new approach to the application of conbercept in the treatment of AMD. We established that in some of the studies included in our meta-analysis, conbercept exerted a more pronounced effect in the therapy of AMD than the control treatments. Therefore, conbercept can be considered as an anti-VEGF drug that deserves wide popularization for AMD treatment.

Conclusion
==========

In conclusion, conbercept exerts more positive effects on the long-term BCVA improvement in AMD patients than triamcinolone and TTT. Our findings indicate that conbercept has a therapeutic effect that is identical to that of ranibizumab, but conbercept reduces the concentration of serum VEGF during the period of treatment. In addition, conbercept has a therapeutic effect that is identical to that of ranibizumab but is superior to the one of TTT in the long-term treatment of AMD patients. Nonetheless, long-term data on the effectiveness and safety of this treatment method are required to confirm these findings.
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![Cochrane risk of bias of included studies (n=13 studies).](cia-13-051Fig1){#f1-cia-13-051}

![Flowchart of the literature review and study selection process. (**A**) The BCVA values obtained after 1-month treatment of conbercept compared with ranibizumab in AMD patients; (**B**) the level of CRT after 3-month treatment of conbercept compared with ranibizumab in AMD patients; (**C**) VEGF serum levels obtained after 1 month of treatment of conbercept compared with ranibizumab in AMD patients.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** BCVA, best-corrected visual acuity; AMD, age-related macular degeneration; CRT, central retinal thickness; VEGF, anti-vascular endothelial growth factor; SMD, standard mean differences; WMD, weighted mean difference.](cia-13-051Fig2){#f2-cia-13-051}

![Comparison of the effect between conbercept and ranibizumab treatments on BCVA and CRT improvement in AMD therapy. (**A**) Forest plots of conbercept and ranibizumab for BCVA improvement in patients with AMD after 1 month of treatment. (**B**) BCVA improvement after 3 months of treatment with conbercept and ranibizumab. (**C**) Serum levels of VEGF. Fixed- and random-effects models were used for the analysis. Diamonds and horizontal lines correspond to the study-specific weighted mean differences (WMD), standard mean differences (SMD), and 95% CI, respectively. WMD and SMD were used in the determination of continuous variables.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** BCVA, best-corrected visual acuity; AMD, age-related macular degeneration; CRT, central retinal thickness; VEGF, anti-vascular endothelial growth factor; CI, confidence interval.](cia-13-051Fig3){#f3-cia-13-051}

![Forest plots of continuous variables of the effect on BCVA improvement in AMD patients after 1 and 3 months of treatment with conbercept vs triamcinolone. The random-effects model was used for the analysis. Horizontal lines are mean 95% CI.\
**Abbreviations:** BCVA, best-corrected visual acuity; AMD, age-related macular degeneration; CI, confidence interval.](cia-13-051Fig4){#f4-cia-13-051}

![Forest plots of dichotomous variables of BCVA improvement after 1 and 3 months of treatment with conbercept and triamcinolone in AMD patients. The random-effects model was used for the analysis. The risk ratios (RR) were employed to compare dichotomous variables. Weights are from random-effects analysis. Horizontal lines are mean 95% CI.\
**Abbreviations:** BCVA, best-corrected visual acuity; AMD, age-related macular degeneration; CI, confidence interval.](cia-13-051Fig5){#f5-cia-13-051}

![Forest plots of continuous variables of CRT improvement in AMD patients after 1 and 3 months of treatment with conbercept vs triamcinolone. The random-effects model was used for the analysis.\
**Abbreviations:** CRT, central retinal thickness; AMD, age-related macular degeneration; RR, risk ratio; CI, confidence interval.](cia-13-051Fig6){#f6-cia-13-051}

![Forest plots of dichotomous variables of the effect on BCVA improvement after 1, 3, and 6 months of treatment with conbercept compared with that achieved after traditional transpupillary thermotherapy (TTT) in AMD patients. The fixed-effects model was used for the analysis.\
**Abbreviations:** BCVA, best-corrected visual acuity; AMD, age-related macular degeneration; CI, confidence interval.](cia-13-051Fig7){#f7-cia-13-051}

![Risk of bias graph. (**A**) Review authors' judgments about each "Risk of bias" item presented as percentages across all included studies; (**B**) the detailed risk of bias values for each article.](cia-13-051Fig8){#f8-cia-13-051}

###### 

Characteristics of the 13 studies

  Name                            Published year   Collection period          Treatment mode              BCVA                 Experiment group   Control group                                                  
  ------------------------------- ---------------- -------------------------- --------------------------- -------------------- ------------------ ------------------- ---------- ----- ---- -------------------- -----------------
  Han et al[@b38-cia-13-051]      2015             Feb 2014 to Jun 2014       1 time                      Standard eye chart   36                 0.1 mL              Kanghong   Tri   36   0.1 mL               JIDA
  Zhu and Liu[@b33-cia-13-051]    2015             May 2013 to April 2014     1 W; 6 M1 Y                 Visual acuity        35                 0.1 mL              NR         Tri   35   0.1 mL               NR
  Ren[@b34-cia-13-051]            2016             June 2013 to June 2015     1/M; Continuously for 3M    Effective rate       40                 0.5 mg              NR         Tri   40   0.1 mL               NR
  Dong et al[@b35-cia-13-051]     2016             Jan 2012 to Jan 2015       1/M; Continuously for 3 M   Snellen Eye Chart    40                 0.05 mL; 10 mg/mL   Kanghong   Tri   40   0.1 mL               Bristol-Myers
  He et al[@b36-cia-13-051]       2015             March 2014 to March 2015   1/M; Continuously for 3 M   Standard eye chart   30                 0.1 mL              NR         Tri   30   0.1 mL               NR
  Song et al[@b37-cia-13-051]     2015             June 2014 to August 2015   1 time                      Central vision       48                 0.5 mg; 0.05 mL     Kanghong   Tri   44   0.5 mg; 0.05 mL      XIANJU
  Liu et al[@b29-cia-13-051]      2015             March 2014 to March 2015   1/M; Continuously for 3 M   Visual acuity        30                 1.5 mg              Kanghong   Ran   30   0.05 mL              Novartis Pharma
  Niu et al[@b30-cia-13-051]      2016             June 2014 to June 2015     1 W; 1 M; 3 M               Standard eye chart   20                 0.1 mL              NR         Ran   20   0.1 mL               NR
  Zhao and Bai[@b31-cia-13-051]   2015             April 2013 to May 2014     1/M; Continuously for 3 M   Standard eye chart   30                 0.05 mL             NR         Ran   31   0.05 mL              NR
  Jin et al[@b32-cia-13-051]      2016             2016                       1 W; 1 M; 3 M               NR                   18                 0.5 mg; 0.05 mL     NR         Ran   10   0.5 mg; 0.05 mL      NR
  Zhang[@b39-cia-13-051]          2015             2013--2014                 1/M; Continuously for 3 M   Effective rate       49                 0.5 mg              Kanghong   TTT   49   Infrared radiation   NR
  Wang[@b40-cia-13-051]           2015             April 2013 to April 2014   1/M; Continuously for 3 M   Effective rate       30                 0.5 mg              NR         TTT   30   Infrared radiation   NR
  Liu et al[@b41-cia-13-051]      2016             Jan 2015 to Dec 2015       1/M; Continuously for 3 M   Effective rate       56                 0.5 mg              Kanghong   TTT   56   Infrared radiation   NR

**Abbreviations:** BCVA, best corrected visual acuity; E-eye, number of experimental group eyes; E-dose, experimental group eye dose; CT, the control group therapy; C-eye, number of control group eyes; C-dose, control group eye dose; W, week; M, month; Y, years; NR, not refer; Tri, triamcinolone; Ran, ranibizumab; TTT, traditional transpupillary thermotherapy.

###### 

Statistical analysis of the results

  Detection index            Control group   M     Data type      Number of studies   Number of eyes        RR/WMD                    95% CI                     Heterogeneity (%)                                  *Z*                                                *P*-value
  -------------------------- --------------- ----- -------------- ------------------- --------------------- ------------------------- -------------------------- -------------------------------------------------- -------------------------------------------------- --------------------------------------------------
  BCVA (logMAR+ effective)   Ran             1     Con            2                   E:50, C:50            −0.11                     (−0.32)--(0.10)            *I*^2^=95%, *P*=0.000                              1.03                                               0.301
  Tri                        1               Dic   2              E:88, C:92          1.28                  0.75--2.17                *I*^2^=89.8%, *P*=0.002    0.89                                               0.371                                              
                             Con             3     E:106, C:106   0.06                (−0.02)--(0.13)       *I*^2^=91.7%, *P*=0.000   1.43                       0.151                                                                                                 
  3                          Dic             2     E:80, C:80     1.21                1.06--1.38            *I*^2^=0.0%, *P*=0.748    2.76                       0.006[\*](#tfn2-cia-13-051){ref-type="table-fn"}                                                      
                             Con             3     E:106, C:106   0.09                0.0--0.18             *I*^2^=79.2%, *P*=0.008   1.98                       0.048[\*](#tfn2-cia-13-051){ref-type="table-fn"}                                                      
  TTT                        1               Dic   3              E:135, C:135        1.12                  1.02--1.22                *I*^2^=53.91%, *P*=0.114   2.37                                               0.018[\*](#tfn2-cia-13-051){ref-type="table-fn"}   
  3                          Dic             3     E:135, C:135   1.23                1.11--1.36            *I*^2^=11.1%, *P*=0.325   4.07                       0.000[\*](#tfn2-cia-13-051){ref-type="table-fn"}                                                      
  6                          Dic             3     E:135, C:135   1.98                1.65--2.39            *I*^2^=0.0%, *P*=0.787    7.21                       0.000[\*](#tfn2-cia-13-051){ref-type="table-fn"}                                                      
  CRT (µm)                   Ran             3     Con            3                   E:80, C:81            0.20                      (−25.02)--(25.41)          *I*^2^=49.8%, *P*=0.136                            0.02                                               0.988
  Tri                        1               Con   3              E:106, C:106        −87.23                (−167.56)--(−6.90)        *I*^2^=86.2%, *P*=0.001    2.13                                               0.033                                              
  3                          Con             3     E:106, C:106   −50.74              (−93.42)--(−8.07)     *I*^2^=62.6%, *P*=0.069   2.33                       0.020[\*](#tfn2-cia-13-051){ref-type="table-fn"}                                                      
  TTT                        1               Con   2              E:79, C:79          −12.72                (−60.94)--(35.50)         *I*^2^=0.0%, *P*=0.906     0.52                                               0.605                                              
  3                          Con             2     E:79, C:79     −19.42              (−67.27)--(28.44)     *I*^2^=0.0%, *P*=0.858    0.80                       0.426                                                                                                 
  6                          Con             2     E:79, C:79     −72.92              (−123.91)--(−22.33)   *I*^2^=0.0%, *P*=0.880    2.83                       0.005[\*](#tfn2-cia-13-051){ref-type="table-fn"}                                                      
  VEGF (ng/L)                Ran             1     Con            2                   E:48, C:40            −0.80                     (−1.24)--(−0.36)           *I*^2^=0.0%, *P*=0.715                             3.54                                               0.000[\*](#tfn2-cia-13-051){ref-type="table-fn"}

**Note:**

Statistically significant.

**Abbreviations:** BCVA, best-corrected visual acuity; CRT, central retinal thickness; VEGF, vascular endothelial growth factor; Ran, ranibizumab; Tri, triamcinolone; TTT, traditional transpupillary thermotherapy; Con, continuous; Dic, dichotomous; E, experiment group; C, control group; WMD, weighted mean difference.
